S&P 500   3,285.52 (+0.28%)
DOW   28,860.55 (+0.48%)
QQQ   221.82 (+0.17%)
AAPL   325.01 (+2.30%)
FB   220.96 (+1.46%)
MSFT   167.02 (+0.94%)
GOOGL   1,452.61 (+0.15%)
AMZN   1,861.75 (+0.46%)
CGC   24.09 (+0.71%)
NVDA   245.37 (-1.05%)
BABA   210.45 (+0.10%)
MU   56.01 (-0.81%)
GE   12.99 (+10.74%)
TSLA   570.93 (+0.71%)
AMD   46.61 (-7.76%)
T   37.61 (-2.51%)
ACB   2.00 (+1.53%)
F   8.93 (-0.45%)
NFLX   345.03 (-1.00%)
BAC   33.40 (+0.48%)
DIS   136.76 (-1.16%)
GILD   64.58 (+0.34%)
S&P 500   3,285.52 (+0.28%)
DOW   28,860.55 (+0.48%)
QQQ   221.82 (+0.17%)
AAPL   325.01 (+2.30%)
FB   220.96 (+1.46%)
MSFT   167.02 (+0.94%)
GOOGL   1,452.61 (+0.15%)
AMZN   1,861.75 (+0.46%)
CGC   24.09 (+0.71%)
NVDA   245.37 (-1.05%)
BABA   210.45 (+0.10%)
MU   56.01 (-0.81%)
GE   12.99 (+10.74%)
TSLA   570.93 (+0.71%)
AMD   46.61 (-7.76%)
T   37.61 (-2.51%)
ACB   2.00 (+1.53%)
F   8.93 (-0.45%)
NFLX   345.03 (-1.00%)
BAC   33.40 (+0.48%)
DIS   136.76 (-1.16%)
GILD   64.58 (+0.34%)
S&P 500   3,285.52 (+0.28%)
DOW   28,860.55 (+0.48%)
QQQ   221.82 (+0.17%)
AAPL   325.01 (+2.30%)
FB   220.96 (+1.46%)
MSFT   167.02 (+0.94%)
GOOGL   1,452.61 (+0.15%)
AMZN   1,861.75 (+0.46%)
CGC   24.09 (+0.71%)
NVDA   245.37 (-1.05%)
BABA   210.45 (+0.10%)
MU   56.01 (-0.81%)
GE   12.99 (+10.74%)
TSLA   570.93 (+0.71%)
AMD   46.61 (-7.76%)
T   37.61 (-2.51%)
ACB   2.00 (+1.53%)
F   8.93 (-0.45%)
NFLX   345.03 (-1.00%)
BAC   33.40 (+0.48%)
DIS   136.76 (-1.16%)
GILD   64.58 (+0.34%)
S&P 500   3,285.52 (+0.28%)
DOW   28,860.55 (+0.48%)
QQQ   221.82 (+0.17%)
AAPL   325.01 (+2.30%)
FB   220.96 (+1.46%)
MSFT   167.02 (+0.94%)
GOOGL   1,452.61 (+0.15%)
AMZN   1,861.75 (+0.46%)
CGC   24.09 (+0.71%)
NVDA   245.37 (-1.05%)
BABA   210.45 (+0.10%)
MU   56.01 (-0.81%)
GE   12.99 (+10.74%)
TSLA   570.93 (+0.71%)
AMD   46.61 (-7.76%)
T   37.61 (-2.51%)
ACB   2.00 (+1.53%)
F   8.93 (-0.45%)
NFLX   345.03 (-1.00%)
BAC   33.40 (+0.48%)
DIS   136.76 (-1.16%)
GILD   64.58 (+0.34%)
Log in

NASDAQ:OSMT - Osmotica Pharmaceuticals Stock Price, Forecast & News

$7.00
+0.24 (+3.55 %)
(As of 01/29/2020 11:00 AM ET)
Today's Range
$6.84
Now: $7.00
$7.09
50-Day Range
$4.90
MA: $6.57
$7.68
52-Week Range
$2.20
Now: $7.00
$8.28
Volume2,626 shs
Average Volume524,206 shs
Market Capitalization$360.64 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms. It also provides women's health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201 for treating Blepharoptos. In addition, the company's non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets to treat major depressive disorder and social anxiety disorder; Hydromorphone ER for treating; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate to treat hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for treating nutritional requirements during pregnancy, as well as Osmodex ANDAs and other ANDAs for various treatments. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OSMT
CUSIPN/A
CIKN/A
Phone908-809-1300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$263.70 million
Cash Flow$3.15 per share
Book Value$7.50 per share

Profitability

Net Income$-109,400,000.00
Net Margins-142.64%

Miscellaneous

Employees466
Market Cap$360.64 million
Next Earnings Date3/25/2020 (Estimated)
OptionableNot Optionable

Receive OSMT News and Ratings via Email

Sign-up to receive the latest news and ratings for OSMT and its competitors with MarketBeat's FREE daily newsletter.


Osmotica Pharmaceuticals (NASDAQ:OSMT) Frequently Asked Questions

What is Osmotica Pharmaceuticals' stock symbol?

Osmotica Pharmaceuticals trades on the NASDAQ under the ticker symbol "OSMT."

How were Osmotica Pharmaceuticals' earnings last quarter?

Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) released its quarterly earnings results on Thursday, November, 14th. The company reported ($2.15) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.30) by $1.85. The firm had revenue of $65.46 million for the quarter, compared to analyst estimates of $49.13 million. Osmotica Pharmaceuticals had a negative net margin of 142.64% and a negative return on equity of 42.38%. View Osmotica Pharmaceuticals' Earnings History.

When is Osmotica Pharmaceuticals' next earnings date?

Osmotica Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Osmotica Pharmaceuticals.

What price target have analysts set for OSMT?

3 analysts have issued 1 year target prices for Osmotica Pharmaceuticals' shares. Their forecasts range from $10.00 to $14.00. On average, they anticipate Osmotica Pharmaceuticals' share price to reach $11.67 in the next twelve months. This suggests a possible upside of 66.7% from the stock's current price. View Analyst Price Targets for Osmotica Pharmaceuticals.

What is the consensus analysts' recommendation for Osmotica Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Osmotica Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Osmotica Pharmaceuticals.

Has Osmotica Pharmaceuticals been receiving favorable news coverage?

News stories about OSMT stock have trended very negative recently, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Osmotica Pharmaceuticals earned a news impact score of -3.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the stock's share price in the next few days. View News Stories for Osmotica Pharmaceuticals.

Are investors shorting Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 936,000 shares, an increase of 147.6% from the December 31st total of 378,000 shares. Based on an average trading volume of 246,700 shares, the short-interest ratio is currently 3.8 days. Approximately 7.2% of the shares of the stock are sold short. View Osmotica Pharmaceuticals' Current Options Chain.

Who are some of Osmotica Pharmaceuticals' key competitors?

What other stocks do shareholders of Osmotica Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Osmotica Pharmaceuticals investors own include Viking Therapeutics (VKTX), Chiasma (CHMA), AT&T (T), Genocea Biosciences (GNCA), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Acasti Pharma (ACST), Adaptimmune Therapeutics (ADAP), Agile Therapeutics (AGRX) and Allena Pharmaceuticals (ALNA).

Who are Osmotica Pharmaceuticals' key executives?

Osmotica Pharmaceuticals' management team includes the folowing people:
  • Mr. Brian A. Markison, Chairman, Pres & CEO (Age 60)
  • Mr. Andrew J. Einhorn, Chief Financial Officer (Age 59)
  • Dr. Tina Marie deVries, Exec. VP of R&D (Age 58)
  • Mr. James D. Schaub, Exec. VP & COO (Age 37)
  • Mr. Christopher A. Klein, Gen. Counsel & Sec. (Age 55)

When did Osmotica Pharmaceuticals IPO?

(OSMT) raised $58 million in an IPO on Thursday, October 18th 2018. The company issued 8,300,000 shares at $7.00 per share. Jefferies, Barclays, RBC Capital MarketsWells and Fargo Securities acted as the underwriters for the IPO.

Who are Osmotica Pharmaceuticals' major shareholders?

Osmotica Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Wedge Capital Management L L P NC (0.39%). View Institutional Ownership Trends for Osmotica Pharmaceuticals.

Which major investors are buying Osmotica Pharmaceuticals stock?

OSMT stock was purchased by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC. View Insider Buying and Selling for Osmotica Pharmaceuticals.

How do I buy shares of Osmotica Pharmaceuticals?

Shares of OSMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Osmotica Pharmaceuticals' stock price today?

One share of OSMT stock can currently be purchased for approximately $7.00.

How big of a company is Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals has a market capitalization of $360.64 million and generates $263.70 million in revenue each year. The company earns $-109,400,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Osmotica Pharmaceuticals employs 466 workers across the globe.View Additional Information About Osmotica Pharmaceuticals.

What is Osmotica Pharmaceuticals' official website?

The official website for Osmotica Pharmaceuticals is http://www.osmotica.com/.

How can I contact Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-809-1300 or via email at [email protected]


MarketBeat Community Rating for Osmotica Pharmaceuticals (NASDAQ OSMT)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  50 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  132
MarketBeat's community ratings are surveys of what our community members think about Osmotica Pharmaceuticals and other stocks. Vote "Outperform" if you believe OSMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OSMT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/29/2020 by MarketBeat.com Staff

Featured Article: Stock Symbol

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel